Pharmaceutical

Oncoinvent’s Radspherin has FDA fast-track status for ovarian cancer

Oncoinvent has received FDA fast track designation for its therapy, Radspherin, to treat peritoneal metastases from ovarian cancer.

Jun 26, 2024 - 04:00
Oncoinvent’s Radspherin has FDA fast-track status for ovarian cancer
Oncoinvent has received FDA fast track designation for its therapy, Radspherin, to treat peritoneal metastases from ovarian cancer.
Read the original article

Tags:

Previous Article

Merck KGaA abandons Phase III trial for $1.08bn head & neck cancer drug

Next Article

Novavax seeks EMA approval for updated JN.1 Covid-19 vaccine

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Pharmalittle: A not-so-new Biogen?; ALS Association and 15 chapters part ways over organizational clashes

STAT+: Pharmalittle: A not-so-new Biogen?; ALS Associat...

Jun 14, 2023

Japan grants patent for BioArctic’s Parkinson’s disease antibody

Japan grants patent for BioArctic’s Parkinson’s disease...

Aug 24, 2023

Signal: Danaher’s $5.7bn acquisition of Abcam faces stand-off with founder

Signal: Danaher’s $5.7bn acquisition of Abcam faces sta...

Sep 15, 2023